|  |  |
| --- | --- |
| **Table S1. Clinical characteristics of the 13 men diagnosised with COVID-19.** |  |
| **Clinical characteristics** | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | Patient 11 | Patient 12 | Patient 13 | n (%) |
| **Date of diagnosis** | 2020/1/31 | 2020/2/1 | 2020/2/10 | 2020/2/12 | 2020/2/15 | 2020/2/22 | 2020/2/23 | 2020/3/1 | 2020/2/13 | 2020/2/14 | 2020/2/14 | 2020/2/15 | 2020/1/30 | - |
| **Age (years)** | 30’  | 30’  | 20’  | 30’  | 30’  | 20’  | 20’  | 20’  | 30’  | 30’  | 20’  | 30’  | 60’  | - |
| **Smoking status** | No | No | No | No | No | No | No | No | No | No | No | No | No | 0  |
| **Drinking status** | No | No | No | No | No | No | No | No | No | No | No | No | No | 0  |
| **Complicated with underlying diseases** | No | No | No | No | No | No | No | No | No | No | No | No | No | 0  |
| **Signs and symptoms on admission** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Fever | Yes | Yes | No | No | Yes | No | No | No | Yes | Yes | Yes | Yes | Yes | 8 (61.5%) |
| Cough | Yes | No | No | No | No | No | No | Yes | Yes | Yes | No | No | Yes | 5 (38.5%) |
| Fatigue | Yes | Yes | No | Yes | No | Yes | No | No | No | No | No | No | Yes | 5 (38.5%) |
| Headache | No | No | Yes | No | No | No | No | No | No | No | No | No | No | 1 (7.7%) |
| Shortness of breath | No | No | No | Yes | No | No | No | No | No | No | No | No | Yes | 2 (15.4%) |
| Sore throat | No | No | No | No | No | Yes | No | No | No | No | No | No | No | 1 (7.7%) |
| Chest distress | No | Yes | No | No | No | No | No | No | No | No | No | No | Yes | 2 (15.4%) |
| Dyspnea | No | No | No | No | No | No | No | No | No | No | No | No | Yes | 1 (7.7%) |
| **CT evidence of pneumonia** | Ground glass opacity | Normal | Patchy shadowing  | Patchy shadowing  | Patchy shadowing  | Stripe shadowing | Stripe shadowing | Normal | Ground glass opacity | Stripe shadowing | Patchy shadowing  | Patchy shadowing  | Patchy shadowing  | - |
| **Clinical group** | Common | Common | Common | Common | Common | Mild | Asymptomatic | Mild | Common | Common | Common | Common | Severe | - |
| **Treatment** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Antiviral therapy | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 13 (100.0%) |
| Antibiotic therapy | Yes | Yes | No | Yes | Yes | No | No | No | Yes | Yes | Yes | No | Yes | 8 (61.5%) |
| Use of corticosteroid | Yes | No | No | No | No | No | No | No | Yes | No | No | Yes | Yes | 4 (30.8%) |
| Use of interferon | Yes | No | No | No | No | No | Yes | No | No | No | No | Yes | No | 3 (23.1%) |
| Use of immunoglobulin | Yes | No | No | No | No | No | No | No | No | No | No | No | Yes | 2 (15.4%) |
| Mechanical ventilation | No | No | No | No | No | No | No | No | No | No | No | No | Yes | 1 (7.7%) |
| ICU | No | No | No | No | No | No | No | No | No | No | No | No | Yes | 1 (7.7%) |
| **Clinical outcomes**  | Rescoverystage | Discharged | Discharged | Rescoverystage | Discharged | Discharged | Discharged | Discharged | Discharged | Discharged | Discharged | Discharged | Died | - |